JB Chemicals & Pharmaceuticals Limited — Investor Meet, 21-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

J.B. Pharma reported strong Q3 FY26 results with revenues up 11% to INR1,065 Cr, net profit up 22% to INR198 Cr, and operating EBITDA up 13% to INR305 Cr. Gross margins expanded to 69.1% driven by product mix and stable raw material costs. Domestic business grew 10% to INR620 Cr, outperforming the Indian pharma market. International formulations saw robust 20% growth. Management expects continued market outperformance in India, high single-digit international growth for FY26, and maintained operating margins of 27-29%. Future guidance includes 10-12% CDMO growth for FY27. Merger with Torrent is expected to close in Q4.